

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims**

Claim 1 (currently amended) ~~Use of  $\gamma$ -GT inhibitors for the preparation of a pharmaceutical composition for the treatment of~~ A method of treating a degenerative disease in a subject in need thereof, comprising the step of inhibiting  $\gamma$ -GT activity in said subject.

Claim 2 (currently amended) The ~~use~~ method of claim 1, wherein said degenerative disease is a chronic renal disease or an inner ear degenerative condition or injury.

Claim 3 (currently amended) The ~~use~~ method of claim 2 wherein said chronic renal disease is ROS induced.

Claim 4 (currently amended) The ~~use~~ method of claim 3, wherein said chronic renal disease is selected from the group consisting of focal glomerulosclerosis, segmental glomerulosclerosis,

Application No. 10/644,325  
Response dated December 8, 2004  
Response to Restriction Requirement dated October 8, 2004

minimal change nephrosis, inflammatory glomerulopathies, diabetic nephropathy and autoimmune glomerulopathies.

Claim 5 (currently amended) The ~~use~~method of claim 2, wherein said inner ear injury is ROS induced.

Claim 6 (currently amended) The ~~use~~method of claim 5, wherein said ROS induced inner ear injury is sensineural deafness induced by age, physiological status, metabolic status or drugs.

Claim 7 (currently amended) The ~~use~~method of claim 6, wherein said drugs are selected from aminoglycosides or cisplatin derivatives.

Claim 8 (currently amended) The ~~use~~method of claim 2, wherein said inner ear degenerative condition is otosclerosis.

Claim 9 (currently amended) The ~~use~~method of any one of claims 1 to 8, wherein said  $\gamma$ -GT inhibitor is selected from the group consisting of AT-125[[,]] (Acivicin) or its derivatives,  $\gamma$ -glutamyl amino acids and peptides of the general formula  $\gamma$ -Glu-XY, peptides of the general formula (CysGlyX), peptidomimetic glutathion analogues, compounds or derivatives of the

Application No. 10/644,325  
Response dated December 8, 2004  
Response to Restriction Requirement dated October 8, 2004

type L-2-amino-4-boronobutanoic acid (ABBA), and anilides, such as  $\gamma$ -glutamyl-7-amido-4-methylcoumarin ( $\gamma$ -Glu-AMC).

Claim 10 (currently amended) The ~~use~~ method of claim 9, wherein X and Y stand for any naturally occurring aminoacid, a modified aminoacid, a oligopeptide or a polypeptide.